A Blueprint For The Future: St. Louis Expansion Doubles Biologics Production Capacity

In the spirit of providing life-changing biologics for patients, Thermo Fisher Pharma Services is proud to announce the expansion of its St. Louis, Missouri biologics facility.  The expansion will increase the company’s capacity to advance medicines to meet patients’ needs. On September 21st, Thermo Fisher Scientific hosted a public dedication event with elected officials and over 400 employees to commemorate this significant addition.

The $50 million investment, spanning 62,000 square feet, will add 80 new technical jobs and substantially increase Thermo Fisher’s ability to meet the clinical and commercial manufacturing needs of its growing client base. This expansion is a near doubling of the production capacity.  When completed next year, Thermo Fisher Pharma Services will become the largest North American CDMO that is focused on the single-use technology platform. The expansion takes advantage of the Thermo Fisher bioproduction “eco-system” for bioreactors, consumables and factory automation.

The greatly increased production capacity supports Pharma Services’ growing Patheon Biologics Network of four sites around the globe, which are all standardized on the single-use platform as the preferred option in new drug development and commercialization. St. Louis currently provides process development, clinical commercial cGMP manufacturing using both fed batch and perfusion processes.

“The demand for high quality biologics services continues to grow,” said Peter Ercoli, Head of the St. Louis Site. “We are thrilled to have this new space and increased capacity to produce life-changing biologics to meet customers’ and patients’ needs.”

For more information on the St. Louis site, please visit https://www.patheon.com/en-us/About-Us/Sites.